Related Experiment Video
Updated: Aug 4, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
Naciba Benlimame1, Qiang He, Su Jie
1Department of Medicine, Lady Davis Institute of the Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.
Abstract:
The overexpression of members of the ErbB tyrosine kinase receptor family has been associated with cancer progression. We demonstrate that focal adhesion kinase (FAK) is essential for oncogenic transformation and cell invasion that is induced by ErbB-2 and -3 receptor signaling. ErbB-2/3 overexpression in FAK-deficient cells fails to promote cell transformation and rescue chemotaxis deficiency. Restoration of FAK rescues both oncogenic transformation and invasion that is induced by ErbB-2/3 in vitro and in vivo. In contrast, the inhibition of FAK in FAK-proficient invasive cancer cells prevented cell invasion and metastasis formation. The activation of ErbB-2/3 regulates FAK phosphorylation at Tyr-397, -861, and -925. ErbB-induced oncogenic transformation correlates with the ability of FAK to restore ErbB-2/3-induced mitogen-activated protein kinase (MAPK) activation; the inhibition of MAPK prevented oncogenic transformation. In contrast, the inhibition of Src but not MAPK prevented ErbB-FAK-induced chemotaxis. In migratory cells, activated ErbB-2/3 receptors colocalize with activated FAK at cell protrusions. This colocalization requires intact FAK. In summary, distinct FAK signaling has an essential function in ErbB-induced oncogenesis and invasiveness.
Insights
Focal adhesion kinase (FAK) is crucial for ErbB-2/3 receptor signaling in cancer. FAK promotes oncogenic transformation and cell invasion, and its inhibition halts metastasis, highlighting its role in cancer progression.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- ErbB tyrosine kinase receptors are frequently overexpressed in cancers, driving tumor progression.
- The role of focal adhesion kinase (FAK) in ErbB-mediated oncogenesis is not fully understood.
Purpose of the Study:
- To investigate the essential role of FAK in oncogenic transformation and cell invasion driven by ErbB-2 and ErbB-3 receptor signaling.
- To elucidate the molecular mechanisms by which ErbB signaling activates FAK and downstream pathways.
Main Methods:
- Utilized FAK-deficient and FAK-proficient cancer cell lines.
- Assessed oncogenic transformation and cell invasion in vitro and in vivo.
- Analyzed FAK phosphorylation and MAPK activation.
- Investigated receptor colocalization using microscopy.
Main Results:
- FAK is essential for ErbB-2/3-induced oncogenic transformation and cell invasion; FAK restoration rescued these phenotypes in FAK-deficient cells.
- FAK inhibition prevented invasion and metastasis in FAK-proficient cancer cells.
- ErbB-2/3 activation induced FAK phosphorylation at specific tyrosine residues (Tyr-397, -861, -925).
- ErbB-induced transformation correlated with FAK-mediated MAPK activation, while chemotaxis required FAK-Src signaling.
Conclusions:
- FAK signaling is indispensable for ErbB-induced oncogenesis and invasiveness.
- Distinct FAK signaling pathways mediate different aspects of ErbB-driven cancer progression, including transformation, invasion, and chemotaxis.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade
MAPK Signaling Cascades
Intracellular Signaling Affects Focal Adhesions
Some...

